Purpose: COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chlo￾roquine for the treatment of COVID-19.
Methods: PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in pa￾tients with COVID-19.
Results: We included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper, two national guideline documents) and 23 ongoing clinical trials in China. Chloroquine seems to be effective in limiting the replication of SARS-CoV-2 (virus causing COVID-19) in vitro.
Conclusions: There is rationale, pre-clinical evidence of effectiveness and evidence of safety from long-time clinical use for other indications to justify clinical research on chloroquine in patients with COVID-19. However, clinical use should either adhere to the Monitored Emergency Use of Unregistered Interventions (MEURI)  framework or be ethically approved as a trial as stated by the World Health Organization. Safety data and data from high-quality clinical trials are urgently needed.

Submit your work at https://www.scitechnol.com/submission/ or send an e-mail attachment to the Editorial Office or  pharmasci@scitecjournals.com
Please provide me your acceptance for the same!
Best Regards,
Editorial Assistant
Journal of Pharmaceutical Sciences & Emerging Drugs
E-mail:  editor.jpsed@scitechnol.com 
What’sapp No.: +1-579-679-8957